Hangzhou Tigermed Consulting Co., Ltd. is a contract research organization that provides services in China and internationally. The company offers clinical trial operations, including clinical pharmacology, regulatory affairs, medical translation, pharmacovigilance, and real-world research for drugs and medical devices. It also provides laboratory services, data management, statistical analysis, and preclinical and clinical development services. Founded in 2004, it is headquartered in Hangzhou, China.
Tigermed posts 413 million yuan loss in first half of 2026
Tigermed disclosed its 2026 semi-annual report on August 29. In the first half, total operating revenue reached 3.708 billion yuan, up 14.06 percent year on year, but net profit attributable to the parent company was a loss of 413 million yuan, compared with a profit of 383 million yuan in the same period last year. Non-GAAP net profit was 278 million yuan, up 31.78 percent year on year, and net cash flow from operating activities was 426 million yuan, up 4.2 percent. During the reporting period, total non-recurring gains and losses were negative 691 million yuan, including a negative 481 million yuan change in fair value of financial assets held. As of the close on August 28, the company's price-to-earnings ratio on a trailing twelve-month basis was about 469.64 times, price-to-book ratio about 2.2 times, and price-to-sales ratio about 5.89 times.
A-share CRO sector surges over 7%, 15 stocks jump more than 10%
The A-share CRO sector surged on the morning of August 7, with the sector index climbing 7.37% to top all sector gainers. Among the 41 constituent stocks, 15 rose more than 10%, including Bide Pharmaceutical, Yaokang Bio, Baihua Pharmaceutical, Apeloa Pharmaceutical, and Asymchem hitting their daily limit up, while another 17 stocks such as BioMap, Joinn Laboratories, Tigermed, and WuXi AppTec gained over 5%. Earnings were the main driver, after BioMap released a profit forecast the previous evening, projecting attributable net profit of 236 million to 246 million yuan for the first half of 2026, a year-on-year increase of 3.92 to 4.13 times. So far, eight CRO companies have reported half-year results or profit forecasts, with six expecting double-digit or higher growth. Joinn Laboratories and Medicilon had previously forecast first-half profit to double. Sector leader WuXi AppTec reported in its half-year results this week that attributable net profit reached 11.08 billion yuan in the first half, up 29.43% year-on-year, surpassing 10 billion yuan for the first time in a first half. It also raised its full-year 2026 revenue guidance to between 58.5 billion and 60.5 billion yuan, with continuing operations revenue growth raised to 35% to 39%. The turnaround in CRO earnings stems from rising orders, as a sustained recovery in global pharmaceutical investment and financing drives renewed demand for innovative drug R&D. BioMap said its two major business lines achieved dual-engine growth, while WuXi AppTec's continuing operations backlog reached 66.43 billion yuan as of end-June, up 25.2% year-on-year. A research note from China Post Securities argued that overseas R&D outsourcing demand is steadily recovering, and a boost in domestic R&D outsourcing demand is expected to materialize in 2026.
WuXi AppTec half-year net profit tops 10 billion yuan for the first time, triggering multiple limit-up moves across the pharmaceutical sector
WuXi AppTec released its 2026 half-year report, with first-half net profit attributable to the parent company surpassing 10 billion yuan for the first time to reach 11.08 billion yuan, up 29.43 percent year on year. The results triggered multiple limit-up moves in the CXO and pharmaceutical sectors across both A-shares and Hong Kong stocks on August 4. WuXi AppTec's A-shares hit the 10 percent daily limit up that day, while its Hong Kong shares closed 11.17 percent higher. The company's first-half revenue was 28.9 billion yuan, up 38.93 percent year on year, and it raised its full-year revenue guidance to a range of 58.5 billion to 60.5 billion yuan. Buoyed by WuXi AppTec's performance, A-share companies such as GemPharmatech, Porton Pharma Solutions, and Medicilon rose over 13 percent, while Hong Kong-listed GenScript Biotech gained over 11 percent, and Pharmaron, Asymchem, and Tigermed climbed more than 5 percent. Several CXO firms had previously issued positive profit alerts. Pharmaron expects first-half net profit to grow 34 to 45 percent year on year, Joinn Laboratories forecasts a staggering 884.9 to 1,377.4 percent surge in net profit attributable to the parent, and Medicilon anticipates swinging to a profit. The innovative drug segment also strengthened, with Biopuris and HitGen rising over 14 percent, while Luoxin Pharmaceuticals, Jimin Health, and ZBD Pharmaceutical hit the 10 percent daily limit up. Meanwhile, Alphamab announced it has granted overseas rights for its TROP2/HER3 bispecific antibody-drug conjugate SKN016 to Pathos AI, in a deal with a total potential value exceeding 2.2 billion US dollars.
Tigermed Repurchases 20.96 Million Shares for 824 Million Yuan
As of July 31, 2026, Tigermed has repurchased 20.96 million shares, accounting for 2.4347% of total share capital, with a total repurchase amount of 824 million yuan and a repurchase price range of 38.22 yuan to 42.78 yuan per share. In the first quarter of 2026, the company achieved revenue of 1.801 billion yuan and net profit attributable to the parent of 49.04 million yuan.
China